Valuation: Supernus Pharmaceuticals, Inc.

Market Cap 2.81B 2.46B 2.27B 2.1B 3.98B 268B 4.04B 27.11B 10.65B 132B 10.56B 10.33B 454B P/E 2026 *
109x
P/E 2027 * 32.4x
Enterprise Value 2.81B 2.46B 2.27B 2.1B 3.98B 268B 4.04B 27.11B 10.65B 132B 10.56B 10.33B 454B EV / Sales 2026 *
3.24x
EV / Sales 2027 * 2.75x
Free-Float
95.54%
Yield 2026 *
-
Yield 2027 * -
1 day-0.59%
1 week+0.85%
Current month+4.19%
1 month+9.12%
3 months-4.38%
6 months-5.65%
Current year-2.49%
1 week 47.04
Extreme 47.04
51.37
1 month 42.45
Extreme 42.45
51.37
Current year 42.45
Extreme 42.45
59.68
1 year 32.2
Extreme 32.2
59.68
3 years 21.99
Extreme 21.99
59.68
5 years 21.99
Extreme 21.99
59.68
10 years 13.12
Extreme 13.12
61.25
Manager TitleAgeSince
Chief Executive Officer 64 22/12/2005
Director of Finance/CFO 67 23/08/2021
Compliance Officer 63 01/01/2012
Director TitleAgeSince
Director/Board Member 64 22/12/2005
Chairman 81 10/08/2016
Director/Board Member 80 16/11/2010
Date Insider Type Main position Quantity % Market Cap.
03-16Fiscal year

Chief Technology Officer

321,750 0.5738%
03-13Others

Founder

60,000 0.1070%
03-12Sell

Director

5,369 0.0096%
Change 5-day change 1-year change 3-year change Capi.($)
-0.59%+0.85%+46.32%+58.89% 2.81B
-1.22%-4.65%+48.20%+14.95% 305B
+0.07%-4.09%+23.85%-6.68% 69.44B
-3.08%-4.09%+33.33%+104.89% 9.04B
-0.40%-3.84%+6.28%+1.15% 8.56B
+2.74%-4.41%-16.17%+11.80% 4.3B
+1.60%-9.66%+14.10%+29.75% 4.09B
+1.63%-2.70%-38.68%+21.29% 3.4B
+2.24%-2.33%+10.24%-21.40% 2.14B
+2.44%-3.48%-17.93%+27.01% 1.81B
Average +0.54%-2.81%+10.95%+24.17% 41.07B
Weighted average by Cap. -0.89%-4.36%+40.65%+13.32%

Financials

2026 *2027 *
Net sales 867M 759M 700M 646M 1.23B 82.71B 1.25B 8.36B 3.28B 40.74B 3.26B 3.19B 140B 1.02B 895M 825M 762M 1.45B 97.56B 1.47B 9.86B 3.87B 48.06B 3.84B 3.76B 165B
Net income 25.92M 22.68M 20.92M 19.32M 36.65M 2.47B 37.27M 250M 98.14M 1.22B 97.34M 95.22M 4.19B 92.99M 81.34M 75.03M 69.3M 131M 8.87B 134M 896M 352M 4.37B 349M 342M 15.02B
Net Debt - -
Logo Supernus Pharmaceuticals, Inc.
Supernus Pharmaceuticals, Inc. is a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases. The Company's diverse neuroscience portfolio includes approved treatments for attention-deficit hyperactivity disorder (ADHD), dyskinesia in Parkinson's Disease (PD) patients receiving levodopa-based therapy, hypomobility in PD, postpartum depression (PPD), epilepsy, migraine, cervical dystonia, and chronic sialorrhea. The Company is developing a range of CNS product candidates including new potential treatments for epilepsy, depression, ADHD, and other CNS disorders. Its products marketed in the United States include Qelbree, GOCOVRI, Oxtellar XR, Trokendi XR, APOKYN, XADAGO, MYOBLOC, ONAPGOTM (formerly known as SPN-830), and ZURZUVAE. Qelbree (viloxazine extended-release capsules) is a non-stimulant product indicated for the treatment of ADHD in adults and pediatric patients 6 years and older.
Employees
778
Date Price Change Volume
10/07/26 $48.46 -0.59% 1,126,231
09/07/26 $48.75 -3.35% 1,296,246
08/07/26 $50.44 +5.21% 1,430,876
07/07/26 $47.94 +1.48% 1,017,845
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BB
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
6
Last Close Price
48.46USD
Average target price
63.50USD
Spread / Average Target
+31.04%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. SUPN Stock